{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:35:27Z","timestamp":1791819327092,"version":"4.3.4"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004853","name":"CUHK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Faculty of Medicine"},{"DOI":"10.13039\/501100001692","name":"Croucher Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001692","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amidex Fondation \u2018Emergence & Innovation\u2019"}],"content-domain":{"domain":["bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biochemical Sciences"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.tibs.2020.11.010","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T22:18:43Z","timestamp":1606429123000},"page":"351-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Nucleic Acid-Based Technologies Targeting Coronaviruses"],"prefix":"10.1016","volume":"46","author":[{"given":"Thi Khanh","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija Shahed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2892-6318","authenticated-orcid":false,"given":"Wai-Lung","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibs.2020.11.010_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1099\/jgv.0.001170","article-title":"ICTV virus taxonomy profile: Nodaviridae","volume":"100","author":"Sahul Hameed","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.tibs.2020.11.010_bb0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0030","first-page":"3","article-title":"Properties of coronavirus and SARS-CoV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays. J. Pathol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.omtn.2019.12.004","article-title":"Improved nucleic acid therapy with advanced nanoscale biotechnology","volume":"19","author":"Weng","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tibs.2020.11.010_bb0040","article-title":"Advancements in nucleic acid based therapeutics against respiratory viral infections","volume":"8","author":"Asha","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibs.2020.11.010_bb0050","first-page":"528","article-title":"siRNA could be a potential therapy for COVID-19","volume":"19","author":"Ghosh","year":"2020","journal-title":"EXCLI J."},{"key":"10.1016\/j.tibs.2020.11.010_bb0055","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0060","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tibs.2020.11.010_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/v10010040","article-title":"CRISPR-Cas targeting of host genes as an antiviral strategy","volume":"10","author":"Chen","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.tibs.2020.11.010_bb0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcdb.2019.04.004","article-title":"CRISPR-Cas based targeting of host and viral genes as an antiviral strategy","volume":"96","author":"Koujah","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0075","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00168-19","article-title":"Host-directed antiviral therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.tibs.2020.11.010_bb0080","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.01294-10","article-title":"Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2","volume":"85","author":"B\u00f6ttcher-Friebertsh\u00e4user","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s10096-008-0495-5","article-title":"siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells","volume":"27","author":"Lu","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.tibs.2020.11.010_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1976","article-title":"A review on current status of antiviral siRNA","volume":"28","author":"Qureshi","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2019.03.010","article-title":"Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector","volume":"166","author":"Li","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0100","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA proofreading: molecular basis and therapeutic targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tibs.2020.11.010_bb0105","article-title":"Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir","author":"Lo","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.tibs.2020.11.010_bb0110","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0120","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibs.2020.11.010_bb0125","doi-asserted-by":"crossref","first-page":"110195","DOI":"10.1016\/j.biopha.2020.110195","article-title":"New understanding of the damage of SARS-CoV-2 infection outside the respiratory system","volume":"127","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tibs.2020.11.010_bb0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1164\/rccm.200707-1022OC","article-title":"Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis","volume":"178","author":"Xu","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1165\/rcmb.2011-0158OC","article-title":"Development and preclinical efficacy of novel transforming growth factor-\u03b21 short interfering RNAs for pulmonary fibrosis","volume":"46","author":"D\u2019Alessandro-Gabazza","year":"2012","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219182","article-title":"Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis","volume":"14","author":"Beumer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.tibs.2020.11.010_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3109\/08958378.2014.907587","article-title":"Local and systemic tolerability of a 2\u2019O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-\u03b1 delivery by inhalation in mouse and monkey","volume":"26","author":"Fey","year":"2014","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.tibs.2020.11.010_bb0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/cmi.2009.7","article-title":"The effects of aerosolized STAT1 antisense oligodeoxynucleotides on rat pulmonary fibrosis","volume":"6","author":"Wang","year":"2009","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1196\/annals.1348.047","article-title":"Multitargeted approach using antisense oligonucleotides for the treatment of asthma","volume":"1082","author":"Allakhverdi","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0165","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1021\/acsnano.0c04006","article-title":"Nanotechnology for COVID-19: therapeutics and vaccine research","volume":"14","author":"Chauhan","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.tibs.2020.11.010_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.04.042","article-title":"Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer","volume":"258","author":"Karaki","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibs.2020.11.010_bb0175","unstructured":"Barth\u00e9l\u00e9my, P. et al. Institut National de la Sante et de la Recherche Medicale (INSERM). Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain, 001516"},{"key":"10.1016\/j.tibs.2020.11.010_bb0180","unstructured":"Barth\u00e9l\u00e9my, P. et al. Institut National de la Sante et de la Recherche Medicale (INSERM). Hydrophobically modified antisense oligonucleotides comprising a ketal group, 001517"},{"key":"10.1016\/j.tibs.2020.11.010_bb0185","unstructured":"Barth\u00e9l\u00e9my, P. et al. Institut National de la Sante et de la Recherche Medicale (INSERM). Evaluation de l\u2019autonanovectorisation de l'oligonucl\u00e9otide anti-TCTP comme strat\u00e9gie innovante pour le traitement des cancers de prostate r\u00e9sistants \u00e0 la castration, 16349"},{"key":"10.1016\/j.tibs.2020.11.010_bb0190","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tibs.2020.11.010_bb0195","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.4161\/hv.29553","article-title":"mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer","volume":"10","author":"Rausch","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.tibs.2020.11.010_bb0200","first-page":"2004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0205","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: a primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.tibs.2020.11.010_bb0210","series-title":"Antisense Therapy","article-title":"Antisense oligonucleotides, a novel developing targeting therapy","author":"Karaki","year":"2019"},{"key":"10.1016\/j.tibs.2020.11.010_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-1-4939-8651-4_26","article-title":"Pre-mRNA splicing modulation by antisense oligonucleotides","volume":"1828","author":"Singh","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.tibs.2020.11.010_bb0230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0076-6879(00)13008-3","article-title":"Evaluation of antisense mechanisms of action","volume":"313","author":"Ghosh","year":"2000","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/108729003764097322","article-title":"HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers","volume":"13","author":"Moulton","year":"2003","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.tibs.2020.11.010_bb0240","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1128\/JVI.78.11.5891-5899.2004","article-title":"Antisense morpholino-oligomers directed against the 5\u2019 end of the genome inhibit coronavirus proliferation and growth","volume":"78","author":"Neuman","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0245","doi-asserted-by":"crossref","first-page":"9665","DOI":"10.1128\/JVI.79.15.9665-9676.2005","article-title":"Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers","volume":"79","author":"Neuman","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0250","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1128\/JVI.02360-06","article-title":"Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models","volume":"81","author":"Burrer","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0260","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40259-013-0046-1","article-title":"Emerging targets and novel approaches to Ebola virus prophylaxis and treatment","volume":"27","author":"Choi","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.tibs.2020.11.010_bb0265","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","article-title":"A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus","volume":"107","author":"DeVincenzo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tibs.2020.11.010_bb0270","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.tibs.2020.11.010_bb0275","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.antiviral.2006.10.008","article-title":"Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a\/7b, 3a\/3b and S","volume":"73","author":"Akerstr\u00f6m","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0285","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.febslet.2006.03.066","article-title":"Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus","volume":"580","author":"He","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tibs.2020.11.010_bb0290","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0295","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nature13769","article-title":"Programmable RNA recognition and cleavage by CRISPR\/Cas9","volume":"516","author":"O\u2019Connell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0300","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nature10886","article-title":"RNA-guided genetic silencing systems in bacteria and archaea","volume":"482","author":"Wiedenheft","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0305","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.tim.2017.04.005","article-title":"Antiviral goes viral: harnessing CRISPR\/Cas9 to combat viruses in humans","volume":"25","author":"Soppe","year":"2017","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0310","doi-asserted-by":"crossref","first-page":"591","DOI":"10.15171\/apb.2018.067","article-title":"The impact of CRISPR-Cas system on antiviral therapy","volume":"8","author":"Bayat","year":"2018","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.tibs.2020.11.010_bb0315","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.tibs.2020.11.010_bb0320","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2018.02.028","article-title":"Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein","volume":"70","author":"Yan","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tibs.2020.11.010_bb0325","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41422-020-0290-0","article-title":"Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","volume":"30","author":"Nguyen","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0330","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.tibs.2020.11.010_bb0335","doi-asserted-by":"crossref","first-page":"794528","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.tibs.2020.11.010_bb0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12250-020-00243-0","article-title":"mRNA vaccines: possible tools to combat SARS-CoV-2","volume":"35","author":"Yi","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.tibs.2020.11.010_bb0345","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","article-title":"Advances in mRNA vaccines for infectious diseases","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0350","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibs.2020.11.010_bb0355","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"10.1016\/j.tibs.2020.11.010_bb0360","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-6481-9_6","article-title":"Nucleoside modified mRNA vaccines for infectious diseases","volume":"1499","author":"Pardi","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0370","first-page":"703","article-title":"Vaccines against COVID-19","volume":"39","author":"Locht","year":"2020","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0375","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibs.2020.11.010_bb0380","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0385","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0390","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0395","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0405","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0410","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0415","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: a transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.tibs.2020.11.010_bb0420","first-page":"7052","article-title":"Rational design of antisense oligonucleotides modulating the activity of TLR7\/8 agonists","volume":"48","author":"Alharbi","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0425","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0430","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4155\/bio-2019-0133","article-title":"Immunogenicity for antisense oligonucleotides: a risk-based assessment","volume":"11","author":"Stebbins","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.tibs.2020.11.010_bb0435","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0440","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tibs.2020.11.010_bb0445","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamapediatrics.2017.4360","article-title":"Nusinersen for spinal muscular atrophy: are we paying too much for too little?","volume":"172","author":"Prasad","year":"2018","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.tibs.2020.11.010_bb0450","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tibs.2020.11.010_bb0455","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/138955710791384036","article-title":"Recent progress in chemically modified siRNAs","volume":"10","author":"Gaglione","year":"2010","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.tibs.2020.11.010_bb0460","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibs.2020.11.010_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188593","article-title":"Minimal 2\u2032-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity","volume":"12","author":"Basila","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tibs.2020.11.010_bb0470","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/Cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.tibs.2020.11.010_bb0475","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0480","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41401-019-0322-9","article-title":"CRISPR-Cas9: a powerful tool towards precision medicine in cancer treatment","volume":"41","author":"Xing","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.tibs.2020.11.010_bb0485","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibs.2020.11.010_bb0490","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s12276-020-0407-z","article-title":"The emerging role of RNA modifications in the regulation of mRNA stability","volume":"52","author":"Boo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.tibs.2020.11.010_bb0495","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tibs.2020.11.010_bb0500","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40885-020-00147-x","article-title":"The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms","volume":"26","author":"McLachlan","year":"2020","journal-title":"Clin. Hypertens"}],"container-title":["Trends in Biochemical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968000420302954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968000420302954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:43:14Z","timestamp":1760823794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968000420302954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0968000420302954"],"URL":"https:\/\/doi.org\/10.1016\/j.tibs.2020.11.010","relation":{},"ISSN":["0968-0004"],"issn-type":[{"value":"0968-0004","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleic Acid-Based Technologies Targeting Coronaviruses","name":"articletitle","label":"Article Title"},{"value":"Trends in Biochemical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibs.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}